AbstractBySubCategory

Prognostic and Predictive Markers

Biomarkers and Inflammatory Signatures

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab. Razvan Cristescu

01

Association of diversity and composition of the gut microbiome with differential responses to PD-1 based therapy in patients with metastatic melanoma. Vancheswaran Gopalakrishnan

02

Association of soluble PD-L1 (sPD-L1) with decreased survival in metastatic melanoma. Roxana Stefania Dronca

04

Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN). Robert L. Ferris

05

Prevalence and clinical implications of T-cell immunoglobulin mucin type-1 (TIM-1) in multiple tumor types. Abdel Halim

34

Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers. Shridar Ganesan

35

Blood-based predictive biomarkers for overall survival (OS) in patients (pts) receiving the immunotherapy sipuleucel-T (sip-T). William K. Oh

36

Neutrophil lymphocyte ratio (NLR) as a predictor of outcomes with immune checkpoint inhibitor (ICI) therapy in genitourinary cancer and melanoma. Ghayathri Jeyakumar

37

Outcomes with immune checkpoint inhibitor use in lung cancer patients with hepatic metastases. Srikala Addepalli

38

Correlation of PD-L1 expression with p16INK4A expression in nonoropharyngeal head and neck squamous cell carcinoma. San-Chi Chen

39

Immune characterization of the programmed death receptor pathway in high-risk prostate cancer. Shaheen Riadh Alanee

40

The difference in prognostic value of tumour-infiltrating T cells according to adjuvant chemotherapy in radiochemonaïve gastroesophageal cancer. Maria Christina Svensson

41

Immunosenescence and cancer immunotherapy. Graham P. Pawelec

42

The pan-cancer, pan-biomarker landscape for precision immuno-oncology. Howard L. McLeod

43

Tumor mutational load in gynecological and breast cancer. Filipa Lynce

44

Predictive roles of tumor infiltrating lymphocyte subtypes to neoadjuvant chemotherapy response in triple negative breast cancer. N. Ansarinejad

45

Variability in the use of cut-off points with different commercial and lab-developed assays for PD-L1 expression testing in the NSCLC clinical setting in the United States. Pieter De Richter

46

The prognostic impact of tumor-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite. Jonna Berntsson

47

Total tumor burden as predictive tool of response and survival of patients with metastatic melanoma treated with nivolumab. Milton Jose Barros e Silva

48

Single-cell cytokine profiling of tumor-infiltrating T cells to measure patient responses to anti-PD-1 therapy. Sean Mackay

49

Potential role of hypovitaminosis D in renal cell carcinoma patients treated with immune-checkpoint inhibitors. Melissa Bersanelli

50

Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy. Tuba Nur Gide

51

Feasibility of miR-9, miR-21, and miR-155 as alternative biomarkers in both HPV-positive and HPV-negative cervical cancers. Dawn Chung

52

The prognostic impact of CD3, CD8, FoxP3, and IL17 tumor-infiltrating immune cells in periampullary cancer differs by morphological type and adjuvant chemotherapy. Carl Fredrik Warfvinge

53

A radiosensitivity gene signature and PD-L1 status to predict clinical outcome of patients with invasive breast carcinoma in the cancer genome atlas (TCGA) dataset. In Ah Kim

54

Clinical and immunologic variables associated with outcomes following combination ipilimumab and nivolumab immunotherapy in melanoma. Samuel Rosner

55

Flow cytometric detection of MDSC populations in unfractionated blood. C. Marcela Diaz-Montero

56

Prognostic value of PD-L1+CD4+ T cells in non-small cell lung cancer (NSCLC) patients treated with a PD-1 inhibitor. Kiriaki E. Vetsika

58

Skin test results with common and melanoma antigens compared to clinical outcomes of melanoma patients treated with intralesional (IL) dinitrochorobenzene (DNCB) or IL bacillus Calmette-Guerin (BCG). Max H. Cohen

59

Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028. Melissa Amber Burgess

60

Response to nivolumab in radiation induced, BRCA-2 N372H variant, programed death ligand-1 negative, pleomorphic undifferentiated sarcoma. Yevgeniya Gora Foster

61

Neurological adverse events from checkpoint inhibition: A comprehensive review of literature. Ahmad Daher

62

A multi-institutional study of immunosuppressed and immunocompetent patients with cutaneous squamous cell carcinoma of the head and neck treated with definitive surgery and radiotherapy: Outcomes after disease recurrence. Shlomo A. Koyfman

63

Pattern of tumor-infiltrating lymphocytes (TILs) and PD-L1 expression in primary and metastatic epithelial ovarian cancer (EOC). Soizick Jeanne Lynette Mesnage

64